<span item_type="fundamental" item_id="0e2ce3a128e3cf21bdbe3a08c4a79b0d" counter_id="ST/US/RFL" env="prod"></span><span item_type="announcement" item_id="658397182350787201" env="prod"></span><p>Revenue: As of FY2026 Q3, the actual value is USD 179 K.</p><p>EPS: As of FY2026 Q3, the actual value is USD -0.08.</p><p>EBIT: As of FY2026 Q3, the actual value is USD -6.59 M.</p><p></p><h3>Financial Results for the Three Months Ended April 30, 2026</h3><h4>Net Loss</h4><p>Rafael Holdings, Inc. reported a net loss attributable to Rafael Holdings, Inc. of - $4.2 million, or - $0.08 per share, for the three months ended April 30, 2026, compared to a net loss of - $4.8 million, or - $0.19 per share, in the prior year period. The year-over-year increase in net loss is primarily due to the consolidation of Cyclo Therapeutic’s expenses following its acquisition in March 2025. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390026067555/ea029432001ex99-1.htm"></span></p><h4>Revenue</h4><p>Total revenue for the three months ended April 30, 2026, was $179 thousand, down from $362 thousand in the prior year period. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390026067555/ea029432001ex99-1.htm"></span> Infusion Technology revenue was $0, compared to $42 thousand in the prior year. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390026067555/ea029432001ex99-1.htm"></span> Rental – Third Party revenue increased to $60 thousand from $49 thousand. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390026067555/ea029432001ex99-1.htm"></span> Rental – Related Party revenue increased to $30 thousand from $28 thousand. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390026067555/ea029432001ex99-1.htm"></span> Product revenue decreased to $89 thousand from $243 thousand. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390026067555/ea029432001ex99-1.htm"></span></p><h4>Operating Expenses</h4><p>Research and development expenses were $4.9 million for the three months ended April 30, 2026, an increase from $3.0 million in the prior year period, primarily due to the inclusion of Cyclo’s R&amp;D spending. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390026067555/ea029432001ex99-1.htm"></span> General and administrative expenses were $2.1 million, a decrease from $3.2 million in the prior year period, attributed to reductions in payroll, stock-based compensation, and professional fees, partially offset by Cyclo’s expenses. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390026067555/ea029432001ex99-1.htm"></span></p><h4>Loss from Operations</h4><p>Loss from operations was - $6,870 thousand, compared to - $5,913 thousand in the prior year period. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390026067555/ea029432001ex99-1.htm"></span></p><h4>Other Income and Expenses</h4><p>Interest income was $286 thousand, down from $472 thousand in the prior year period. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390026067555/ea029432001ex99-1.htm"></span> Interest expense was - $6 thousand, compared to - $165 thousand in the prior year period. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390026067555/ea029432001ex99-1.htm"></span> A gain on settlement of accounts payable and convertible notes payable of $3,723 thousand was recorded, compared to $0 in the prior year period. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390026067555/ea029432001ex99-1.htm"></span></p><h3>Financial Results for the Nine Months Ended April 30, 2026</h3><h4>Net Loss</h4><p>For the nine months ended April 30, 2026, Rafael Holdings, Inc. reported a net loss attributable to Rafael Holdings, Inc. of - $20.5 million, or - $0.40 per share, compared to a net loss of - $18.4 million, or - $0.73 per share, in the prior year period. This increase in net loss is primarily due to the consolidation of Cyclo Therapeutic’s expenses following its acquisition in March 2025. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390026067555/ea029432001ex99-1.htm"></span></p><h4>Revenue</h4><p>Total revenue for the nine months ended April 30, 2026, was $630 thousand, up from $567 thousand in the prior year period. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390026067555/ea029432001ex99-1.htm"></span> Infusion Technology revenue was $0, compared to $93 thousand in the prior year. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390026067555/ea029432001ex99-1.htm"></span> Rental – Third Party revenue increased to $173 thousand from $147 thousand. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390026067555/ea029432001ex99-1.htm"></span> Rental – Related Party revenue increased to $89 thousand from $84 thousand. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390026067555/ea029432001ex99-1.htm"></span> Product revenue increased to $368 thousand from $243 thousand. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390026067555/ea029432001ex99-1.htm"></span></p><h4>Operating Expenses</h4><p>Research and development expenses were $16.9 million for the nine months ended April 30, 2026, significantly higher than $5.3 million in the prior year period, due to the inclusion of Cyclo’s spending. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390026067555/ea029432001ex99-1.htm"></span> General and administrative expenses were $7.3 million, a decrease from $8.3 million in the prior year period, primarily due to reductions in payroll and stock-based compensation, partially offset by Cyclo’s expenses. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390026067555/ea029432001ex99-1.htm"></span></p><h4>Loss from Operations</h4><p>Loss from operations was - $23,678 thousand, compared to - $16,396 thousand in the prior year period. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390026067555/ea029432001ex99-1.htm"></span></p><h4>Other Income and Expenses</h4><p>Interest income was $1,023 thousand, down from $1,529 thousand in the prior year period. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390026067555/ea029432001ex99-1.htm"></span> Interest expense was - $327 thousand, compared to - $490 thousand in the prior year period. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390026067555/ea029432001ex99-1.htm"></span> A gain on settlement of accounts payable and convertible notes payable of $3,958 thousand was recorded, compared to $0 in the prior year period. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390026067555/ea029432001ex99-1.htm"></span></p><h3>Balance Sheet Highlights as of April 30, 2026</h3><p>Cash and cash equivalents were $30.5 million, compared to $52.8 million as of July 31, 2025. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390026067555/ea029432001ex99-1.htm"></span> Total assets were $91,990 thousand, down from $114,109 thousand as of July 31, 2025. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390026067555/ea029432001ex99-1.htm"></span> Total liabilities were $11,187 thousand, down from $15,738 thousand as of July 31, 2025. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390026067555/ea029432001ex99-1.htm"></span> Total equity was $80,803 thousand, down from $98,371 thousand as of July 31, 2025. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390026067555/ea029432001ex99-1.htm"></span></p><h3>Outlook / Guidance</h3><p>Rafael Holdings, Inc. expects to submit its New Drug Application (NDA) in the second half of calendar year 2026, following a pre-NDA meeting with the FDA. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390026067555/ea029432001ex99-1.htm"></span> This step is anticipated to provide a clear and expedited path for its lead candidate, Trappsol® Cyclo™, for Niemann-Pick Disease Type C1 (NPC). <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390026067555/ea029432001ex99-1.htm"></span> The company believes this positions Rafael Holdings, Inc. to potentially transition into a commercial-stage biotechnology company. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1713863/000121390026067555/ea029432001ex99-1.htm"></span></p>

【Bulls vs. Bears】SpaceX's biggest-ever IPO is here — are you in? Share your bullish or bearish trades (equities and leveraged/inverse ETFs welcome) to boost your odds of winning!Full rules in the pinned post under this topic🎁 Rewards· Live trade screenshot — top 5: SPCX-branded tumbler· Top insight — 3 winners: baseball cap· Top 5 by engagement: HK$10 stock cash coupon· Original comment (30+ chars): 200 Task Coins *Genuine insights and real trades get priority — AI-generated content discouraged

<p>【Bulls vs. Bears】SpaceX's biggest-ever IPO is here — are you in? Share your bullish or bearish trades (equities and leveraged/inverse ETFs welcome) to boost your odds of winning!</p><p>Full rules in the pinned post under this topic</p><p>🎁 Rewards</p><p>· Live trade screenshot — top 5: SPCX-branded tumbler</p><p>· Top insight — 3 winners: baseball cap</p><p>· Top 5 by engagement: HK$10 stock cash coupon</p><p>· Original comment (30+ chars): 200 Task Coins *Genuine insights and real trades get priority — AI-generated content discouraged</p>

Rafael-B | 8-K: FY2026 Q3 Revenue: USD 179 K